Compare SUVEN LIFE with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES GLENMARK PHARMA SUVEN LIFESCIENCES/
GLENMARK PHARMA
 
P/E (TTM) x 20.4 12.6 161.5% View Chart
P/BV x 4.1 1.8 228.9% View Chart
Dividend Yield % 0.5 0.5 95.2%  

Financials

 SUVEN LIFESCIENCES   GLENMARK PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
GLENMARK PHARMA
Mar-19
SUVEN LIFESCIENCES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs338712 47.5%   
Low Rs169484 35.0%   
Sales per share (Unadj.) Rs52.1349.6 14.9%  
Earnings per share (Unadj.) Rs6.832.8 20.8%  
Cash flow per share (Unadj.) Rs8.644.3 19.3%  
Dividends per share (Unadj.) Rs1.502.00 75.0%  
Dividend yield (eoy) %0.60.3 176.8%  
Book value per share (Unadj.) Rs65.3198.6 32.9%  
Shares outstanding (eoy) m127.28282.17 45.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.91.7 284.6%   
Avg P/E ratio x37.118.2 203.6%  
P/CF ratio (eoy) x29.613.5 219.5%  
Price / Book Value ratio x3.93.0 129.1%  
Dividend payout %22.06.1 359.9%   
Avg Mkt Cap Rs m32,272168,625 19.1%   
No. of employees `0001.112.0 9.0%   
Total wages/salary Rs m66120,561 3.2%   
Avg. sales/employee Rs Th6,132.28,196.0 74.8%   
Avg. wages/employee Rs Th611.11,708.1 35.8%   
Avg. net profit/employee Rs Th803.5768.5 104.6%   
INCOME DATA
Net Sales Rs m6,63598,655 6.7%  
Other income Rs m2422,081 11.6%   
Total revenues Rs m6,877100,736 6.8%   
Gross profit Rs m1,60415,858 10.1%  
Depreciation Rs m2213,259 6.8%   
Interest Rs m383,346 1.1%   
Profit before tax Rs m1,58711,335 14.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m7183,756 19.1%   
Profit after tax Rs m8699,250 9.4%  
Gross profit margin %24.216.1 150.4%  
Effective tax rate %45.233.1 136.5%   
Net profit margin %13.19.4 139.8%  
BALANCE SHEET DATA
Current assets Rs m6,23266,968 9.3%   
Current liabilities Rs m1,49040,211 3.7%   
Net working cap to sales %71.527.1 263.5%  
Current ratio x4.21.7 251.1%  
Inventory Days Days8683 103.7%  
Debtors Days Days8381 101.7%  
Net fixed assets Rs m4,04333,322 12.1%   
Share capital Rs m127282 45.1%   
"Free" reserves Rs m8,18355,770 14.7%   
Net worth Rs m8,31056,052 14.8%   
Long term debt Rs m1835,738 0.0%   
Total assets Rs m10,389132,888 7.8%  
Interest coverage x43.14.4 982.5%   
Debt to equity ratio x00.6 0.3%  
Sales to assets ratio x0.60.7 86.0%   
Return on assets %8.79.5 92.1%  
Return on equity %10.516.5 63.4%  
Return on capital %19.517.8 109.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62262,998 8.9%   
Fx outflow Rs m1,79922,859 7.9%   
Net fx Rs m3,82240,140 9.5%   
CASH FLOW
From Operations Rs m35613,242 2.7%  
From Investments Rs m-279-6,990 4.0%  
From Financial Activity Rs m-225-7,387 3.0%  
Net Cashflow Rs m-148-2,971 5.0%  

Share Holding

Indian Promoters % 63.4 48.3 131.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 6.9 -  
FIIs % 0.0 34.4 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.5 347.6%  
Shareholders   37,287 56,727 65.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   DISHMAN PHARMA  ELDER PHARMA  VENUS REMEDIES  PANACEA BIOTECH  CADILA HEALTHCARE  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

WPI Inflation Data, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)

On Monday, Indian share markets witnessed negative trading activity throughout the day and ended lower.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Sep 16, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES - DR. DATSONS LABS COMPARISON

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS